Author(s): Mustafa Turhan Sahin

Journal Name: Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Formerly Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents

Volume 6 , Issue 3 , 2007

Become EABM
Become Reviewer
Call for Editor


Alefacept is a fully human fusion protein, being the first biologic agent approved for the treatment of chronic, moderate to severe plaque-type psoriasis. Its dual mechanism of action involves inhibition of T-cell activation and selective reduction of memory T cells. It has a slow onset of action, peaking approximately 18 weeks after the first injection. However, it is associated with long remissions without the need for maintenance therapy in psoriatic patients and its efficacy improves with subsequent courses with a high safety profile. The mechanism of action, the results of the clinical trials, its efficacy, pharmacodynamic effects on circulating lymphocytes, and safety and tolerability of alefacept are summarized in this review. Current treatment guidelines are also presented.

Keywords: Psoriasis area severity index, lymphocyte-function associated antigen-3, memory T cells, Alopecia areata, Quality of life

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Published on: 01 March, 2012
Page: [211 - 216]
Pages: 6
DOI: 10.2174/187152307781368229
Price: $65

Article Metrics

PDF: 4